FindTrial
Sign In

Cost, benefits, safety and medication adherence of anti-TB medicine in patients of drug-resistant tuberculosis in major hospital of South Gujarat

Pharmaco-economic variables, safety and adherence of Bedaquiline(BDQ) based regimen in drug resistant tuberculosis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/066018
Enrollment
200
Registered
2024-04-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A150- Tuberculosis of lung

Interventions

Control Intervention1: NIL: NIL

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Adult (=18 years of age) of any gender on BDQ-based regimen and other regimen for DR-TB

Exclusion criteria

Exclusion criteria: Patients not willing to participate Drug resistant TB patient on anti-retroviral therapy

Design outcomes

Primary

MeasureTime frame
Cost effectiveness analysis outcome in natural units of effectiveness Cost minimization in monetary value Cost utility in QALY Cost benefit in DALY Safety and adherence of the DR-TB regimen in DR-TB PatientsTimepoint: Cost effectiveness analysis outcome in natural units of effectiveness 12 months Cost minimization in monetary value 12 months Cost utility in QALY 12 months Cost benefit in DALY 12 months Safety and adherence of the DR-TB regimen in DR-TB Patients 12 months—

Secondary

MeasureTime frame
not applicable as its single outcome studyTimepoint: not applicable—

Countries

India

Contacts

Public ContactDr Chetna Patel

Government Medical College, Surat

drchetnapatel2012@yahoo.com7990618600

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026